![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 8, 6719-6725, February 22, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§¶,
,
, and
§**
From the
Ottawa Health Research Institute, Ottawa
Hospital, Ottawa K1Y 4E9, Canada and the Departments of
§ Biochemistry, Microbiology, and Immunology,
Cellular and Molecular Medicine, and ** Obstetrics and
Gynaecology, University of Ottawa,
Ottawa K1N 6N5, Canada
Received for publication, August 21, 2001, and in revised form, November 15, 2001
| |
ABSTRACT |
|---|
|
|
|---|
Several recent studies have demonstrated that
insulin-like growth factor (IGF)-1-induced mitogen-activated protein
kinase (MAP kinase) activation is abolished by pertussis toxin,
suggesting that trimeric G proteins of the Gi class
are novel cellular targets of the IGF-1 signaling pathway. We report
here that the intracellular domain of the Xenopus IGF-1
receptor is capable of binding to the Xenopus homolog of
mammalian GIPC, a PDZ domain-containing protein previously identified
as a binding partner of Gi-specific GAP (RGS-GAIP). Binding
of xGIPC to xIGF-1 receptor is independent of the kinase activity of
the receptor and appears to require the PDZ domain of xGIPC. Injection
of two C-terminal truncation mutants that retained the PDZ domain
blocked IGF-1-induced Xenopus MAP kinase activation and
oocyte maturation. While full-length xGIPC injection did not
significantly alter insulin response, it greatly enhanced human
RGS-GAIP in stimulating the insulin response in frog oocytes. This
represents the first demonstration that GIPC·RGS-GAIP complex
acts positively in IGF-1 receptor signal transduction.
Insulin-like growth factor 1 (IGF-1)1 exerts its
biological roles by activating the intrinsic protein tyrosine kinase
activity of the IGF-1 receptor. The activated IGF-1 receptor
autophosphorylates its cytoplasmic domain and phosphorylates insulin
receptor substrate 1 (IRS-1) and many other protein substrates.
Phosphorylation of these protein substrates leads to changes in
multiple intracellular signaling pathways including the Ras-Raf-MAP
kinase pathway and the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt
pathway (1). However, these same signaling pathways are also similarly
regulated by insulin/insulin receptor and other growth factors such as
epidermal growth factor and platelet-derived growth factor. Clearly,
simple tissue- and time-specific expressions of the receptors and/or components of these signaling pathways do not fully explain the distinct biological activities of these various growth factors.
Several recent studies have demonstrated that IGF-1 receptors activate
heterotrimeric G proteins in some cell types. Luttrell et
al. (2) first demonstrated that IGF-1-induced MAP kinase activation in rat 1 fibroblasts was inhibited by either treating cells
with pertussis toxin or transfecting them with a G We have been studying IGF-1 receptor signaling in the induction of
oocyte maturation in Xenopus laevis (6, 7). We have used the
cytoplasmic portion of the xIGF-1 receptor in a yeast two-hybrid screen
in an attempt to isolate potential downstream signaling proteins. In
this paper, we report the identification of the Xenopus
homolog of GIPC as an xIGF-1 receptor-binding protein and provide
evidence supporting a functional role for xGIPC in the regulation of G
protein signaling downstream of the xIGF-1 receptor in the induction of
oocyte maturation.
Animal and Oocyte Manipulation--
All procedures involving
live oocytes were carried out in a room maintained at between 18 and
20 °C. Sexually mature, oocyte-positive X. laevis were
purchased from NASCO and maintained according to local animal care
guidelines. The frogs were injected with pregnant mare serum
gonadotropin (Sigma, 50 IU/frog) 3-10 days before operations. A
fragment of ovary was removed surgically under hypothermia. Stage VI
oocytes were manually defolliculated and stored in oocyte incubation
medium OR2 (82.5 mM NaCl, 2.5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM Na2HPO4, 5 mM Hepes,
pH 7.8).
Cloning and cDNA Manipulation--
The nucleotide sequence
encoding the cytoplasmic domain (amino acids 958-1358) of the
Xenopus IGF-1R (7) was PCR-amplified using the
following primers: forward primer, 5'-TATG AAT TCT AAG AAG AGA AAC AGC
AAC C-3'; reverse primer, 5'-TAT GAA TTC ACT GAT ACA GCG GG-3'. The
amplified cDNA was digested with EcoRI, treated with the
Klenow fragment, and ligated into the pAS2
(CLONTECH) vector that had been digested with
BamHI and treated with the Klenow fragment. The
resulting clone, designated pAS-xIGF-1Rcyto, expressed
a fusion protein between the GAL4 DNA-binding domain and the xIGF-1R
cytoplasmic domain. The kinase-deficient mutant of xIGF-1R
(xIGF-1RKAcyto) in pAS2 was constructed by the two-step PCR
procedure (8) using the same forward and reverse primers (above) in
combination with the following internal primers changing the
catalytically essential Lys-1029 to Ala: forward primer, 5'-A GTT GCC ATA GCG ACG GTC AAC G-3'; reverse primer, 5'-C GTT GAC CGT CGC
TAT GGC AAC TTT C-3'. To create xIGF-1Rcyto
and xIGF-1RKAcyto for transfection or mRNA synthesis,
the same PCR products were digested with EcoRI and ligated
into pCS2+Myc previously treated with EcoRI.
Upon sequence analysis, YA 5-2, the clone identified in the yeast
two-hybrid screen, was found to have its open reading frame (ORF)
(xGIPC) inserted in a reverse orientation relative to the GAL4
activation domain (AD). To clone xGIPC in-frame with the GAL4AD,
a 5' PCR primer was designed to amplify the coding region (5'-TAT GAA
TTC ATG CCT CTG GGA TTG CGC GTA AAG-3'). This primer, along with
a pGAD10 (two-hybrid vector)-specific primer, was used to amplify the
ORF. The PCR product was digested with EcoRI and ligated
into the pGAD10 previously digested with EcoRI. To create an
xGIPC for transfection and mRNA synthesis, the same PCR product was
digested with EcoRI and treated with Klenow before ligation into pCS2+HA previously digested with XbaI and treated with Klenow.
pCS2+HA was modified from pCS2+ (9) as follows. Two complementary
oligonucleotides were made to code for the hemagglutinin (HA)
epitope (YPYDVPDYA) with a translation initiation codon and cohesive
BamHI ends. The sequences of the two oligonucleotides were as follows: forward, 5'-GAT CCA CCA TGT ACC CAT ACG ATG TTC CAG
ATT ACG CTT CCA TG-3'; reverse, 5'-GAT CCA TGG AAG CGT AAT CTG GAA CAT
CGT ATG GGT ACA TGG TG-3'. The oligonucleotides were annealed to
each other and then directly ligated into pCS2+ vector previously
digested with BamHI.
Subclones of xGIPC for mapping the binding region of xGIPC and for
injection into oocytes were similarly generated by PCR using primers
containing an EcoRI site. The PCR fragments were ligated
into either pGAD10 vector or pCS2+HA vector. The resulting clones
generated were fusion proteins with the GAL4AD or a HA tag,
respectively. For the sake of brevity, only the amino acids comprising
the various constructs are indicated in the figures. To reconstitute
full-length xGIPC, we PCR-amplified xGIPC-(1-320) with a
reversed primer encoding 11 extra amino acids (GAIGDAKQGRF) derived
from the sequence of the Xenopus expressed sequence
tag clone (10).
The human GAIP coding sequence was PCR-amplified from a human brain
cDNA library (a gift of J. K. Ngsee) using the
following primers: forward primer, 5'-TAT GAA TTC A AT GCC CAC
CCC GCA TGA GG-3'; reverse primer, 5'-TAT GAA TTC TGT GCT GCT GGG GGC
GGC C-3'. The amplified sequence was digested with
EcoRI and inserted at the EcoRI site of
pCS2+ or pCS2+MT (9), resulting in the expression of an untagged or
Myc-tagged version of human GAIP. The identity of the sequence was
confirmed by DNA sequence determination.
Yeast Two-hybrid Analysis--
These procedures are essentially
the same as those described in the Yeast Protocol Handbook
provided by CLONTECH. Saccharomyces cerevisiae strain Y190 was co-transformed with the bait plasmid (pAS-xIGF-1Rcyto) and a X. laevis oocyte
cDNA library constructed in the pGAD10 vector
(CLONTECH). Transformants were plated on 150-mm
synthetic dropout medium (Yeast Protocol Handbook,
CLONTECH)/His Polyclonal Antibodies against xGIPC--
An internal
HindIII fragment of xGIPC, encoding amino acids 216-305,
was excised and inserted into pGEX-KT (11). Glutathione S-transferase fusion proteins were induced and purified by
binding to glutathione-agarose beads. Immunization of rabbits was
carried out according to Harlow and Lane (12). Immune sera were used without further processing.
Co-immunoprecipitation Experiments--
COS-7 cells were
maintained in Dulbecco's modified Eagle's medium supplemented with
10% fetal calf serum, 50 units/ml penicillin-streptomycin, and 2 ml/liter Fungizone (Invitrogen) at 37 °C in a humidified atmosphere
containing 5% CO2.
Transient transfection of COS-7 cells was accomplished using
LipofectAMINE (Invitrogen). Briefly, cells in a six-well dish at 70%
confluence were washed once with PBS and incubated with 1 ml of
OPTI-MEM medium containing 5 µl of LipofectAMINE reagent and 0.25 µg of each plasmid for 18 h. Following the transfection, the
medium was changed to Dulbecco's modified Eagle's medium with 10%
fetal calf serum with antibiotics. The cells were allowed to grow for a
further 24-30 h and lysed for co-immunoprecipitation or kinase assays.
Transiently transfected COS-7 cells were washed with PBS and then lysed
with 200 µl of ice-cold PBS-Lysis buffer (13) (10 mM
phosphate buffer, pH 7.5, 150 mM NaCl, 1% Triton X-100,
100 µM phenylmethylsulfonyl fluoride, 10 µg/ml
leupeptin, 100 µM sodium orthovanadate). The lysate was
cleared by a 10-min centrifugation at 15,000 × g. 150 µl of the cleared lysate was added to 450 µl of PBS-Lysis buffer
containing 10 µl of anti-Myc- or anti-HA-Sepharose beads (14).
Lysates were incubated at 4 °C with rocking for 2 h.
Immunocomplexes were washed five times with PBS-Lysis buffer; after
washing, 20 µl of 2× Laemmli sample buffer was added, and the
samples were separated using SDS-PAGE. The proteins were transferred to
a nitrocellulose membrane for Western blotting.
Co-immunoprecipitation experiments using frog oocyte extracts were
performed essentially the same way. Oocytes were injected with the
various mRNA and incubated overnight. Extracts were prepared in
PBS-Lysis buffer (10 µl/oocyte) and subjected to immunoprecipitation (200-400 µl of extract with 5 µl of either preimmune serum or anti-xGIPC immune serum).
Protein Kinase Assays--
Protein kinase assays were performed
on immunoprecipitated xIGF-1Rcyto or
xIGF-1RKAcyto. Briefly, immunoprecipitation procedures were
carried out as above with the exception that the last wash step was
done with kinase buffer (50 mM Hepes, pH 6.9, 1 mM EDTA, 0.1% Triton X-100). After the final wash, 23 µl
of kinase buffer were added, and the reaction was started with the
addition of 10 µCi of [
MPF extracts were prepared and assayed according to Nebreda and Hunt
(15). Briefly, oocytes were crushed in extraction buffer (20 mM Hepes, pH 7.3, 80 mM glycerophosphate, 20 mM EGTA, 15 mM MgCl2, 1 mM dithiothreitol, 0.75 µM ATP, 0.15 mM NaF, 10 µg/ml leupeptin, 200 µM
phenylmethylsulfonyl fluoride, 25 µg/ml benzamidine; 20 µl/oocyte).
Following centrifugation, 8 µl of lysates were used in a kinase
reaction (total volume of 12 µl) with the addition of 2 µg of
histone H1, 5 µCi of [ We inserted the cytoplasmic domain of xIGF-1 receptor (7) into the
bait vector pAS2. The resultant plasmid (pAS-xIGF-1Rcyto) encodes an HA epitope tag followed by the DNA-binding domain of GAL4
and then by the xIGF-1 receptor cytoplasmic domain. We also constructed
similar bait (pAS-xIGF-1RKAcyto) with a single point mutation changing the catalytically essential lysine 1029 to alanine. Transforming yeast with each plasmid resulted in expression of the
fusion protein with the anticipated size as indicated by both anti-xIGF-1 receptor blots and anti-HA blots (Fig.
1). As expected, pAS-xIGF-1Rcyto was phosphorylated on tyrosine, whereas
tyrosine phosphorylation of pAS-xIGF-1RKAcyto was
undetectable.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

scavenger (
ARK-CT), suggesting the involvement of a pertussis toxin-sensitive G protein (i.e. of the Gi class). This study
further suggests that the released G
subunits, rather than the
activated GTP-bound G
subunit, is responsible for IGF-1-induced MAP
kinase activation. Similar results have since been obtained using human
intestinal smooth muscle cells (3), 3T3-L1 mouse pre-adipose cells (4), and rat cerebellar granule neurons (5). These latter studies further
demonstrated that the IGF-1 receptor forms a complex with a G protein
subunit of the Gi class with its associated G
subunit (and presumably G
subunit) (4, 5). Kuemmerle and Murthy (3)
were able to demonstrate that IGF-1 selectively activated G
i2 but not G
i1,
G
i3, or G
q in the same cells. As
heterotrimeric G proteins are known to be associated with, and
activated by, heptahelical G protein-coupled receptors, it remains
unclear how IGF-1/IGF-1 receptors activate the Gi proteins.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/Leu
/Trp
/3-amino-1,2,4-triazole
(50 mM) plates and incubated at 30 °C until colonies
reached 1-2 mm.
-Galactosidase assays for the detection of
potential positive clones were performed according to the protocols
supplied by CLONTECH. Potential positive clones were grown in liquid synthetic dropout medium/Leu
, and
the pGAD10 library plasmid was isolated and transformed into
Escherichia coli strain MH6 by electroporation. The
transformants were plated on M9 media (11 mM
Na2HPO4, 22 mM
KH2PO4, 8.5 mM NaCl, 19 mM NH4Cl, 1 mM MgSO4,
100 µM CaCl2, 2 mg/ml thiamine, 20 mg/liter uracil, 100 µg/ml ampicillin) and incubated at 37 °C for 20 h. The isolated plasmid was used in co-transformation assays with the
original bait plated on synthetic dropout
medium/Leu
/Trp
plates. Colonies were tested
for filter-based
-galactosidase activity. Yeast protein extraction
for immunoblotting was carried out using the urea/SDS method supplied
by CLONTECH.
-32P]ATP, 1 µM ATP, and 5 mM MnCl2. The
kinase reaction was carried out at room temperature for 30 min and was
stopped with the addition of 2× Laemmli sample buffer.
-32P]ATP (10 mCi/ml, >3000
Ci/mmol), and 33 µM ATP. Kinase reactions were carried
out at room temperature for 20 min before the addition of 12 µl of
2× Laemmli sample buffer. Proteins were separated on a 10% SDS-PAGE,
dried, and visualized by autoradiography.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (48K):
[in a new window]
Fig. 1.
xIGF-1Rcyto is active in
yeast. Extracts from control yeast or yeast transformed with
pAS-xIGF-1Rcyto or with pAS-xIGF-1RKAcyto were
separated by SDS-PAGE and immunoblotted with the indicated antibodies.
Arrows indicate GAL4 fusion proteins containing
xIGF-1Rcyto or xIGF-1RKAcyto. pY,
phosphotyrosine.
Using pAS-xIGF-1Rcyto as bait, we screened an oocyte cDNA library constructed in the pGAD10 vector (encoding the GAL4AD) (by CLONTECH). One particular clone, YA5-2, caught our attention since it contained an ORF highly homologous to a mammalian gene, GIPC, previously identified as a binding partner for a Gi-specific GTPase-activating protein (RGS-GAIP or GAIP) (16). We thought that perhaps GIPC might provide a functional link between IGF-1 receptor and Gi protein signaling. However, the ORF of 320 amino acids, which included a candidate translation start site but lacked a translation termination codon, was inserted in pGAD10 with a reverse orientation. Therefore xGIPC could not have been made as part of a GAL4AD fusion protein. This clone was therefore initially discarded as "false positive" until one of us (R. A. B.) found, in searching the literature, that the ADH1 termination sequences actually contain functional promoter sequences capable of initiating transcription opposite to the ADH promoter in pGAD10 (17). Consequently xGIPC could have been expressed in yeast from the promoter contained within the ADH1 termination sequences as a nonfusion protein.
The cloned xGIPC was sequenced from both directions, and the sequences
assembled and compared with GIPC from several other species (Fig.
2). From these comparisons, it seemed
that YA 5-2 only contained partial xGIPC coding sequences lacking the
extreme C terminus of perhaps as few as 11 amino acids. However,
repeated attempts to amplify the missing C terminus by either 3'-rapid amplification of cDNA ends or anchored PCR were unsuccessful (data not shown).
|
We carried out further yeast two-hybrid assays to confirm that xGIPC
was indeed capable of interacting with xIGF-1Rcyto and attempted to define the region of xGIPC responsible for the
interaction. xGIPC-(1-320), the PDZ domain, or the arbitrarily defined
N or C terminus (Fig. 3A) were
PCR-amplified and inserted into pGAD10. Co-transformation of each
plasmid with xIGF-1Rcyto, xIGF-1RKAcyto, or a
control plasmid xIRS-1-(3-500) (13) was carried out. We found
that GAL4AD-xGIPC-(1-320), like YA 5-2, interacted strongly with
xIGF-1Rcyto. Both YA 5-2 and GAL4AD-xGICP-(1-320) also
interacted strongly with the kinase-deficient mutant
xIGF-1RKAcyto. Neither was able to interact with
xIRS-1-(3-500), cloned in the same vector (13), or the vector alone
(not shown). A deletion mutant (xGIPCN-PDZ) missing the
C terminus behaved very similarly to YA 5-2 or xGIPC-(1-320) (Fig.
3B). However, none of the three regions of xGIPC (the N terminus, the PDZ domain, or the C terminus), when expressed separately with GAL4AD, were able to interact with xIGF-1Rcyto or
xIGF-1RKAcyto (Fig. 3B).
|
We decided to carry out binding experiments in transiently transfected
COS-7 cells following an unsuccessful attempt to demonstrate co-immunoprecipitation of endogenous xIGF-1 receptor and xGIPC in frog
oocytes (see below). To facilitate these experiments, we subcloned
xIGF-1Rcyto or xIGF-1RKAcyto into pCS2+Myc (9) and xGIPC or its truncation mutants (Fig. 3A) into pCS2+HA.
Transient transfection of Myc-xIGF-1Rcyto or
Myc-xIGF-1RKAcyto resulted in similar levels of the two
proteins, recognized by anti-Myc (Fig.
4A, lower panel).
Immunoprecipitation followed by an in vitro kinase assay
confirmed that Myc-xIGF-1RKAcyto was indeed deficient in
catalytic activity (Fig. 4A, upper panel).
Co-transfection of each plasmid with HA-xGIPC followed by
co-immunoprecipitation experiments clearly indicated that xGIPC was
able to bind both the kinase-active and kinase-deficient cytoplasmic
domain of the xIGF-1 receptor (Fig. 4B, lanes 7 and 8). Lanes 5 and 6 in Fig. 4B represent HA immunoprecipitation from extracts derived
from cells expressing only the Myc-tagged proteins, indicating that the
co-immunoprecipitation observed in Fig. 4B, lanes
7 and 8, were not due to the overexpressed Myc fusion
proteins being "pulled down" by anti-HA antibodies
nonspecifically.
|
We wished to determine whether overexpression of xGIPC-(1-320) and the
various truncation mutants had any effect on IGF-1 receptor signaling
in frog oocytes. mRNA encoding green fluorescent protein (18) (used
as a control), HA-xGIPC-(1-320), or HA-xGIPCPDZ were
injected into immature oocytes. Following overnight incubation to allow
translation and accumulation of the corresponding proteins, oocytes
were incubated with insulin (200 or 500 nM). We have
previously shown that these concentrations of insulin activate the
endogenous xIGF-1 receptor (7, 19) and ultimately cause oocyte
maturation, indicated by, among other criteria, xMAP kinase activation
and GVBD. Fig. 5A shows that
injection of the PDZ domain mRNA had no significant effect
(compared with similar amount of green fluorescent protein mRNA or
water) on insulin-induced GVBD. In contrast, injection of
xGIPC-(1-320) mRNA severely reduced the ability of insulin to
induce GVBD. Fig. 5B shows a typical experiment where we
analyzed xMAP kinase phosphorylation (indicative of activation (20,
21)) following scoring oocytes for GVBD (Fig. 5A). Again,
xGIPC-(1-320), but not the PDZ domain in isolation, significantly
reduced the ability of insulin to activate xMAP kinase phosphorylation
(activation). Immunoblotting using anti-HA antibodies demonstrated that
both xGIPC-(1-320) and HA-xGIPCPDZ were expressed and
accumulated in oocytes (Fig. 5A, inset).
Similarly, injection of mRNA encoding either the N terminus or the
C terminus of xGIPC did not significantly change insulin-induced xMAP
kinase phosphorylation (Fig. 5C) or GVBD (not shown).
|
A recently deposited Xenopus expressed sequence tag clone
(GenBankTM accession no. AW646188) (10) apparently
contains the missing 3'-end of our xGIPC sequence. This clone contains
240 bp of coding sequence that is identical to the corresponding region
of xGIPC (with the exception, of course, of the 11 extra codons that
are missing from our clone). Full-length xGIPC was therefore generated by PCR amplification of xGIPC-(1-320) with a 3'-primer that contained 11 extra codons (GAIGDAKQGRF). To our surprise, the full-length xGIPC,
unlike xGIPC-(1-320), did not inhibit insulin-induced oocyte maturation assayed by three different criteria: GVBD (Fig.
6A), MPF activation (Fig.
6B), and xMAP kinase phosphorylation (Fig. 6C).
In contrast a C-terminal deletion mutant (xGIPCN-PDZ),
which was capable of binding xIGF-1 receptor cytoplasmic domain in the yeast assays (Fig. 3B), significantly reduced
insulin-induced oocyte maturation. Immunoblotting indicated that xGIPC
and xGIPCN-PDZ were expressed at similar levels in the
respectively injected oocytes (Fig. 6A, inset).
The inhibitory effect of xGIPCN-PDZ was reminiscent of that
of xGIPC-(1-320) (Fig. 5, A and B).
|
To further investigate the mechanism of xGIPC in insulin signaling, we
explored the possible functional interaction between xGIPC and GAIP in
frog oocytes. Human GAIP (hGAIP) cDNA was PCR-amplified and
expressed with or without an N-terminal Myc tag. Our preliminary injection experiments indicated that hGAIP significantly accelerated insulin-induced GVBD (not shown). We used a concentration of insulin (50 nM) that was not sufficient to induce oocyte maturation
in most batches of frog oocytes. Under these conditions, injection of
hGAIP mRNA (either untagged or Myc-tagged) resulted in oocyte maturation in a significant percentage of oocytes (Fig.
7, A and B).
Although xGIPC alone had little effect, it greatly enhanced the ability
of hGAIP in stimulating insulin-induced oocyte maturation (Fig. 7,
A and B). To confirm that xGIPC bound hGAIP in
frog oocytes, we performed co-immunoprecipitation experiments. Oocytes
were injected with Myc-hGAIP alone or together with HA-xGIPC,
HA-xGIPC-(1-320), or HA-xGIPCN-PDZ. Immunoprecipitation
with antibodies against xGIPC pulled down both endogenous xGIPC (not
shown) and all three forms of mRNA-derived xGIPC (Fig.
7C, lower panel). Co-immunoprecipitation of
Myc-hGAIP with the endogenous xGIPC was evident (Fig. 7C,
lane 5 compared with lane 1, which represents
preimmune control). The amounts of Myc-hGAIP co-precipitated in xGIPC
immunoprecipitations increased significantly in all three groups
of oocytes that had been injected with the various xGIPC mRNAs
(Fig. 7C, lanes 6-8 as compared with lane
5). These results clearly indicated the ability of all three forms
of xGIPC to bind Myc-hGAIP. As would be expected, nonspecific binding
of Myc-GAIP in preimmune immunoprecipitations (Fig. 7C,
lanes 1-4) did not change regardless of whether oocytes had
received the xGIPC mRNA injection.
|
| |
DISCUSSION |
|---|
|
|
|---|
The original xGIPC-(1-320) clone (YA 5-2) isolated in the yeast two-hybrid screen was inserted in the pGAD10 vector with a reverse orientation relative to that of GAL4AD. This unusual result meant that xGIPC-(1-320) was not made as a GAL4AD fusion protein or driven by the ADH promoter. Instead it was transcribed from an intrinsic promoter lying within the ADH1 termination sequences (17) and translated as a nonfusion protein. Under this circumstance, xGIPC-(1-320) should bind the bait (GAL4DBD-xIGF-1Rcyto) but should also function as a "transcription activator" capable of replacing the GAL4AD in activating the Gal1-driven reporters in the two-hybrid assay. This is not surprising given that more than 1% of random bacterial genomic fragments demonstrate transcription activator function when fused in frame with the yeast GAL4 DNA-binding domain (22). The common feature of these transcription activators is the relative abundance of acidic amino acids (22). Indeed, xGIPC-(1-320) is an acidic protein (overall pI of 6.16) with a particularly acidic C terminus (pI of 4.71 over the last 114 amino acids). A second possibility was for xGIPC-(1-320) to simultaneously bind the bait and a GAL4AD fusion protein derived from the nonsense direction of xGIPC-(1-320).
A recent study (23) indicates that the PDZ domain of mammalian GIPC is sufficient to mediate interaction to TrkA (receptor for nerve growth factor). Lou et al. (23) have also defined the juxtamembrane domain of TrkA as the likely docking site for the GIPC PDZ domain. Limited, but noticeable, sequence homology was indeed found between the juxtamembrane domains of TrkA and xIGF-1 receptor (not shown). We have not yet determined whether this region of the xIGF-1 receptor is similarly required for interacting with xGIPC. Our data also indicate that both xGIPC-(1-320) and xGIPCN-PDZ are capable of binding to xIGF-1 receptor, consistent with the notion that the PDZ domain is also involved in binding the intracellular domain of xIGF-1 receptor. However, the PDZ domain alone did not suffice to bind xIGF-1 receptor either in yeast two-hybrid assays (Fig. 3B) or in COS cells (not shown). Further studies will be required to clarify the nature of this apparent difference.
Clearly the most interesting implication of our data lies in the possible link between IGF-1 receptor signaling and G protein functions during oocyte maturation. High levels of cAMP are thought to be responsible for maintaining oocyte meiosis arrest (24). Progesterone, the natural maturation-inducing ovarian hormone, binds to the cytoplasmic progesterone receptor (xPR) (25, 26) and triggers a reduction of cAMP by inhibiting oocyte adenylyl cyclase (27, 28). Insulin and IGF-1 can also induce maturation in vitro (29) by activating the endogenous IGF-1 receptor (7). Forskolin, a potent adenylyl cyclase activator, similarly blocks both progesterone-induced and insulin-induced oocyte maturation (30, 31), suggesting that a reduction of cAMP is a necessary event in both cases. It has been reported that insulin is able to stimulate oocyte cAMP phosphodiesterase activity (32). A recent study has provided a possible link between the insulin/IGF-1 receptor and the activation of oocyte phosphodiesterase. Andersen et al. (33) reported that injection of protein kinase B/Akt results in activation of cAMP phosphodiesterase (PDE3) and induction of oocyte maturation. Protein kinase B/Akt is a serine/threonine kinase activated downstream of PI 3-kinase. We (6) and others (34) have previously shown that insulin/IGF-1 receptor activates PI 3-kinase in frog oocytes. Therefore, one signaling pathway may consist of IGF-1 receptor-activated PI 3-kinase-protein kinase B/Akt, which directly or indirectly activates oocyte PDE3 (33) and ultimately results in the reduction of oocyte cAMP.
We propose here that following ligand binding, xIGF-1 receptor
activates an oocyte Gi in addition to the PI
3-kinase/Akt/PDE3 pathway. The co-operation of the two signaling
pathways ensures the required cAMP reduction by inhibiting oocyte
adenylyl cyclase (via Gi
-GTP) and activating oocyte PDE3
(via protein kinase B/Akt). The function of xGIPC is likely to promote
GAIP-mediated Gi
-GTP hydrolysis that timely terminates
the G protein signal and recycles the resulting Gi
-GDP
for another round of G protein activation. It is interesting to note
that several groups have recently demonstrated that IGF-1 receptor
forms a complex with trimeric Gi proteins (4, 5). Whether
the interaction between IGF-1 receptor and Gi is direct or
mediated by other proteins, it is conceivable that xGIPC could function
to link GAIP to the receptor complex. A receptor complex containing
both the signal initiator (IGF-1 receptor) and signal terminator (GAIP)
may be a unique feature to trimeric G protein signaling downstream of
receptor protein tyrosine kinases (such as IGF-1 receptor and TrkA).
The two C-terminally truncated xGIPC mutants, xGIPCN-PDZ or
xGIPC-(1-320), may act in a dominant-negative fashion over the
endogenous xGIPC. The fact that both behaved similarly to full-length
xGIPC in binding xIGF-1R (Fig. 3B) and hGAIP (Fig.
7C) would seem to rule out the simple explanation that the
mutants fail to link GAIP to the IGF-1 receptor. The reasons for the
apparently dominant-negative effect of these mutants therefore remain unknown.
How might the complex of xGIPC and RGS-GAIP stimulate IGF-1 receptor
signaling in frog oocytes? Two nonmutually exclusive possibilities are
considered here. First, overexpression of xGIPC and hGAIP may increase
the IGF-1 receptor-associated GTPase activity of hGAIP toward
endogenous Gi-GTP and hence accelerate recycling of
Gi-GDP for further rounds of activation by the IGF-1
receptor. This clearly would have the net effect of increased
Gi activity, resulting in greater inhibition of oocyte
adenylyl cyclase and reduction of cAMP. Second, the complex of xGIPC
and hGAIP may function downstream of xIGF-1 receptor, independently of
Gi, to activate a maturation-promoting signaling pathway.
| |
ACKNOWLEDGEMENT |
|---|
We thank Hai-Ping Wang for constructing the pCS2+HA vector.
| |
FOOTNOTES |
|---|
* This work was supported by an operating grant from the Canadian Institute of Health Research (to X. J. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Recipient of an Ontario Graduate Scholarship in Science and Technology sponsored by the Ottawa Health Research Institute.

To whom correspondence should be addressed. Tel.: 613-798-5555 (ext. 17752); Fax: 613-761-5411 or 613-761-5365; E-mail:
jliu@ohri.ca.
Published, JBC Papers in Press, January 7, 2002, DOI 10.1074/jbc.M108033200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: IGF-1, insulin-like growth factor 1; MAP, mitogen-activated protein; IRS-1, insulin receptor substrate 1; IGF-1R, IGF-1 receptor; ORF, open reading frame; AD, activation domain; HA, hemagglutinin; PBS, phosphate-buffered saline; MPF, maturation/M phase-promoting factor; GVBD, germinal vesicle breakdown; x, Xenopus; h, human; PDE3, phosphodiesterase 3; PI, phosphatidylinositol.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Cheatham, B., and Kahn, C. R. (1995) Endocr. Rev. 16, 117-142[CrossRef][Medline] [Order article via Infotrieve] |
| 2. |
Luttrell, L. M.,
van Biesen, T.,
Hawes, B. E.,
Koch, W. J.,
Touhara, K.,
and Lefkowitz, R. J.
(1995)
J. Biol. Chem.
270,
16495-16498 |
| 3. |
Kuemmerle, J. F.,
and Murthy, K. S.
(2001)
J. Biol. Chem.
276,
7187-7194 |
| 4. |
Dalle, S.,
Ricketts, W.,
Imamura, T.,
Vollenweider, P.,
and Olefsky, J. M.
(2001)
J. Biol. Chem.
276,
15688-15695 |
| 5. |
Hallak, H.,
Seiler, A. E. M.,
Green, J. S.,
Ross, B. N.,
and Rubin, R.
(2000)
J. Biol. Chem.
275,
2255-2258 |
| 6. | Liu, X. J., Sorisky, A., Zhu, L., and Pawson, T. (1995) Mol. Cell. Biol. 15, 3563-3570[Abstract] |
| 7. |
Zhu, L.,
Ohan, N.,
Agazie, Y.,
Cummings, C.,
Farah, S.,
and Liu, X. J.
(1998)
Endocrinology
139,
949-954 |
| 8. |
Vallette, F.,
Mege, E.,
Reiss, A.,
and Adesnik, M.
(1989)
Nucleic Acids Res.
17,
723-733 |
| 9. |
Turner, D. L.,
and Weintraub, H.
(1994)
Genes Dev.
8,
1434-1447 |
| 10. | Blackshear, P. J., Lai, W. S., Thorn, J. M., Kennington, E. A., Staffa, N. G. J., Moore, D. T., Bouffard, G. G., Beckstrom-Sternberg, S. M., Touchman, J. W., Bonaldo, M. F., and Soares, M. B. (2001) Gene (Amst.) 267, 71-87[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Guan, K., and Dixon, J. E. (1991) Anal. Biochem. 192, 262-267[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Harlow, E., and Lane, D. (eds) (1988) Antibodies: A Laboratory Manual , pp. 106-107, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 13. |
Farah, S.,
Agazie, Y.,
Ohan, N.,
Ngsee, J. K.,
and Liu, X. J.
(1998)
J. Biol. Chem.
273,
4740-4746 |
| 14. | Sheng, Y., Tiberi, M., Booth, R. A., Ma, C., and Liu, X. J. (2001) Curr. Biol. 11, 405-416[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Nebreda, A. R., and Hunt, T. (1993) EMBO J. 12, 1979-1986[Medline] [Order article via Infotrieve] |
| 16. |
De Vries, L.,
Lou, X.,
Zhao, G.,
Zheng, B.,
and Farquhar, M. G.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
12340-12345 |
| 17. |
Chien, C.-T.,
Bartel, P. L.,
Sternglanz, R.,
and Fields, S.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
9578-9582 |
| 18. | Ohan, N., Saborin, J., and Liu, X. J. (2000) Mol. Reprod. Dev. 56, 336-344[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Cummings, C., Zhu, L., Sorisky, A., and Liu, X. J. (1996) Dev. Biol. 175, 338-346[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Posada, J.,
Yew, N.,
Ahn, N. G.,
Vande Woude, G. F.,
and Cooper, J. A.
(1993)
Mol. Cell. Biol.
13,
2546-2553 |
| 21. | Ohan, N., Agazie, Y., Cummings, C., Booth, R., Bayaa, M., and Liu, X. J. (1999) J. Cell Sci. 112, 2177-2184[Abstract] |
| 22. | Ma, J., and Ptashne, M. (1987) Cell 51, 113-119[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
Lou, X.,
Yano, H.,
Lee, F.,
Chao, M. V.,
and Farquhar, M. G.
(2001)
Mol. Biol. Cell
12,
615-627 |
| 24. |
Smith, L. D.
(1989)
Development
107,
685-699 |
| 25. |
Bayaa, M.,
Booth, R., A.,
Sheng, Y.,
and Liu, X. J.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
12607-12612 |
| 26. |
Tian, J.,
Kim, S.,
Hellig, E.,
and Ruderman, J. V.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
14358-14363 |
| 27. |
Sadler, S. E.,
and Maller, J. L.
(1981)
J. Biol. Chem.
256,
6368-6373 |
| 28. | Finidori-Lepicard, J., Schorderet-Slatkine, S., Hanoune, J., and Baulieu, E.-E. (1981) Nature 292, 255-257[CrossRef][Medline] [Order article via Infotrieve] |
| 29. |
El-Etr, M.,
Schorderet-Slatkine, S.,
and Baulieu, E.-E.
(1979)
Science
205,
1397-1399 |
| 30. | Schorderet-Slatkine, S., and Baulieu, E.-E. (1982) Endocrinology 111, 1385-1387[Abstract] |
| 31. | Schorderet-Slatkine, S., and Schorderet, M. (1984) Symp. Soc. Exp. Biol. 38, 67-85[Medline] [Order article via Infotrieve] |
| 32. |
Sadler, S. E.,
and Maller, J. L.
(1987)
J. Biol. Chem.
262,
10644-10650 |
| 33. |
Andersen, C. B.,
Roth, R. A.,
and Conti, M.
(1998)
J. Biol. Chem.
273,
18705-18708 |
| 34. | Deuter-Reinhard, M., Apell, G., Pot, D., Kippel, A., Williams, L. T., and Kavanaugh, M. (1997) Mol. Biol. Cell 17, 2559-2565 |
This article has been cited by other articles:
![]() |
J. Lattin, D. A. Zidar, K. Schroder, S. Kellie, D. A. Hume, and M. J. Sweet G-protein-coupled receptor expression, function, and signaling in macrophages J. Leukoc. Biol., July 1, 2007; 82(1): 16 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Varsano, M.-Q. Dong, I. Niesman, H. Gacula, X. Lou, T. Ma, J. R. Testa, J. R. Yates III, and M. G. Farquhar GIPC Is Recruited by APPL to Peripheral TrkA Endosomes and Regulates TrkA Trafficking and Signaling Mol. Cell. Biol., December 1, 2006; 26(23): 8942 - 8952. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Muders, S. K. Dutta, L. Wang, J. S. Lau, R. Bhattacharya, T. C. Smyrk, S. T. Chari, K. Datta, and D. Mukhopadhyay Expression and Regulatory Role of GAIP-Interacting Protein GIPC in Pancreatic Adenocarcinoma Cancer Res., November 1, 2006; 66(21): 10264 - 10268. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wu, M. O'Donnell, A. D. Gitler, and P. S. Klein Kermit 2/XGIPC, an IGF1 receptor interacting protein, is required for IGF signaling in Xenopus eye development Development, September 15, 2006; 133(18): 3651 - 3660. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ghez, Y. Lepelletier, S. Lambert, J.-M. Fourneau, V. Blot, S. Janvier, B. Arnulf, P. M. van Endert, N. Heveker, C. Pique, et al. Neuropilin-1 Is Involved in Human T-Cell Lymphotropic Virus Type 1 Entry J. Virol., July 15, 2006; 80(14): 6844 - 6854. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Reed, C. Cefalu, B. H. Bellaire, J. A. Cardelli, T. Louis, J. Salamon, M. A. Bloecher, and R. C. Bunn GLUT1CBP(TIP2/GIPC1) Interactions with GLUT1 and Myosin VI: Evidence Supporting an Adapter Function for GLUT1CBP Mol. Biol. Cell, September 1, 2005; 16(9): 4183 - 4201. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Favre-Bonvin, C. Reynaud, C. Kretz-Remy, and P. Jalinot Human Papillomavirus Type 18 E6 Protein Binds the Cellular PDZ Protein TIP-2/GIPC, Which Is Involved in Transforming Growth Factor {beta} Signaling and Triggers Its Degradation by the Proteasome J. Virol., April 1, 2005; 79(7): 4229 - 4237. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Jeanneteau, J. Diaz, P. Sokoloff, and N. Griffon Interactions of GIPC with Dopamine D2, D3 but not D4 Receptors Define a Novel Mode of Regulation of G Protein-coupled Receptors Mol. Biol. Cell, February 1, 2004; 15(2): 696 - 705. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hirakawa, C. Galet, M. Kishi, and M. Ascoli GIPC Binds to the Human Lutropin Receptor (hLHR) through an Unusual PDZ Domain Binding Motif, and It Regulates the Sorting of the Internalized Human Choriogonadotropin and the Density of Cell Surface hLHR J. Biol. Chem., December 5, 2003; 278(49): 49348 - 49357. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Grey, Q. Chen, X. Xu, K. Callon, and J. Cornish Parallel Phosphatidylinositol-3 Kinase and p42/44 Mitogen-Activated Protein Kinase Signaling Pathways Subserve the Mitogenic and Antiapoptotic Actions of Insulin-Like Growth Factor I in Osteoblastic Cells Endocrinology, November 1, 2003; 144(11): 4886 - 4893. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Hu, W. Chen, N. P. Martin, E. J. Whalen, R. T. Premont, and R. J. Lefkowitz GIPC Interacts with the {beta}1-Adrenergic Receptor and Regulates {beta}1-Adrenergic Receptor-mediated ERK Activation J. Biol. Chem., July 3, 2003; 278(28): 26295 - 26301. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang and X. J. Liu A G Protein-coupled Receptor Kinase Induces Xenopus Oocyte Maturation J. Biol. Chem., April 25, 2003; 278(18): 15809 - 15814. [Abstract] [Full Text] [PDF] |
||||